<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37828349</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The value of serum creatinine as biomarker of disease progression in spinal and bulbar muscular atrophy (SBMA).</ArticleTitle><Pagination><StartPage>17311</StartPage><MedlinePgn>17311</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17311</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-44419-6</ELocationID><Abstract><AbstractText>Serum creatinine has been indicated as a potential marker of motor function in SBMA and results form previous longitudinal studies pointed to its decline over time. This is a longitudinal retrospective study investigating creatinine changes over a 36-month-period in 73 patients with SBMA. Severity and progression of the disease was assessed according to serum creatine kinase (CK) values, manual muscle testing (MMT), SBMA functional rating scale (SBMAFRS) score, 6-min-walk test (6MWT) value, and spirometry (forced vital capacity, fVC%) obtained at the baseline and at each of the annual follow-up visits. Baseline serum creatinine concentrations positively correlated with 6MWT, the MMT megascore score of both the upper (ULM) and lower (LLM) limbs and SBMAFRS. No correlation was found with CK or fVC% values. Similar correlation results were achieved at all the subsequent time points. Longitudinal assessments conducted by the generalized estimating equations (GEE) method returned significant changes for SBMAFRS (-&#xa0;1.41 points per year, p&#x2009;&lt;&#x2009;0.001), ULM and LLM (-&#xa0;0.69, p&#x2009;=&#x2009;0.01; and -&#xa0;1.07, p&#x2009;&lt;&#x2009;0.001, respectively), 6MWT (-&#xa0;47&#xa0;m, p&#x2009;&lt;&#x2009;0.001) but not for creatinine (-&#xa0;0.82, p&#x2009;&gt;&#x2009;0.05). We also observed that creatinine levels at baseline did not correlate with changes in the other measures from baseline at each annual visit. Our data do not support a role for serum creatinine as sensitive biomarker of disease progression, and possibily prognosis, in SBMA.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Blasi</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sabbatini</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querin</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Myologie, I-Motion Adult ClinicalTrials Platform, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Department of Neurosciences, Azienda Ospedaliera Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vianello</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertolin</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Genetics Unit, Department of Women and Children's Health, University of Padova, IRP Citt&#xe0; Della Speranza, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pareyson</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Unit of Rare Neurodegenerative and Neurometabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennuto</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegoraro</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xf9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Neuromuscular Center, University of Padova, 35128, Padua, Italy. gianni.soraru@unipd.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37828349</ArticleId><ArticleId IdType="pmc">PMC10570332</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-44419-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-44419-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fischbeck KH. Kennedy disease. J. Inherit. Metab. Dis. 1997;20(2):152&#x2013;158. doi: 10.1023/a:1005344403603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1005344403603</ArticleId><ArticleId IdType="pubmed">9211187</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77&#x2013;79. doi: 10.1038/352077a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352077a0</ArticleId><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahin N, Klein C, Mandrekar J, Sorenson E. Natural history of spinal-bulbar muscular atrophy. Neurology. 2008;70(21):1967&#x2013;1971. doi: 10.1212/01.wnl.0000312510.49768.eb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000312510.49768.eb</ArticleId><ArticleId IdType="pubmed">18490617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorar&#xf9; G, D'Ascenzo C, Nicolao P, Volpe M, Martignago S, Palmieri A, Romeo V, Koutsikos K, Piccione F, Cima V, Pegoraro E, Angelini C. Muscle histopathology in upper motor neuron-dominant amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. 2008;9(5):287&#x2013;293. doi: 10.1080/17482960802206801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802206801</ArticleId><ArticleId IdType="pubmed">18608096</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, Rao P, Mo K, Johansen JA, Lewis G, Kemp MQ. Androgen receptor and Kennedy disease/spinal bulbar muscular atrophy. Horm Behav. 2008;53(5):729&#x2013;740. doi: 10.1016/j.yhbeh.2007.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yhbeh.2007.12.009</ArticleId><ArticleId IdType="pmc">PMC2883265</ArticleId><ArticleId IdType="pubmed">18321505</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L, Tokunaga S, Lopez E, Sopher BL, Bennett CF, Shelton GD, Cleveland DW, La Spada AR. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014;82(2):295&#x2013;307. doi: 10.1016/j.neuron.2014.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.03.001</ArticleId><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, La Spada AR. Motor neuron degeneration in spinal and Bulbar Muscular Atrophy is a skeletal muscle-driven process: Relevance to therapy development and implications for related motor neuron diseases. Rare Dis. 2014;2(1):e962402. doi: 10.4161/2167549X.2014.962402.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/2167549X.2014.962402</ArticleId><ArticleId IdType="pmc">PMC4755247</ArticleId><ArticleId IdType="pubmed">26942099</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bertolin C, Da Re E, Volpe M, Zara G, Pegoraro E, Caretta N, Foresta C, Silvano M, Corrado D, Iafrate M, Angelini L, Sartori L, Pennuto M, Gaiani A, Bello L, Semplicini C, Pareyson D, Silani V, Ermani M, Ferlin A, Sorar&#xf9; G. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J. Neurol. Neurosurg. Psychiatry. 2016;87(8):810&#x2013;816. doi: 10.1136/jnnp-2015-311305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311305</ArticleId><ArticleId IdType="pmc">PMC4975824</ArticleId><ArticleId IdType="pubmed">26503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R, Sorar&#xfa; G, Grunseich C, Fratta P, Zuccaro E, Pennuto M, Rinaldi C. Beyond motor neurons: Expanding the clinical spectrum in Kennedy's disease. J. Neurol. Neurosurg. Psychiatry. 2018;89(8):808&#x2013;812. doi: 10.1136/jnnp-2017-316961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316961</ArticleId><ArticleId IdType="pmc">PMC6204939</ArticleId><ArticleId IdType="pubmed">29353237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Fischbeck KH, Pennuto M, Fratta P, Katsuno M. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA) J. Neurol. Neurosurg. Psychiatry. 2020;91(10):1085&#x2013;1091. doi: 10.1136/jnnp-2020-322949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322949</ArticleId><ArticleId IdType="pubmed">32934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bede P, Marchand-Pauvert V, Pradat PF. Biomarkers of spinal and bulbar muscle atrophy (SBMA): A comprehensive review. Front. Neurol. 2018;9:844. doi: 10.3389/fneur.2018.00844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00844</ArticleId><ArticleId IdType="pmc">PMC6191472</ArticleId><ArticleId IdType="pubmed">30364135</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi Y, Katsuno M, Banno H, Suzuki K, Kawashima M, Atsuta N, Ito M, Watanabe H, Tanaka F, Sobue G. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve. 2008;38(2):964&#x2013;971. doi: 10.1002/mus.21077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21077</ArticleId><ArticleId IdType="pubmed">18642379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist JR, Fornander F, de Stricker BJ, Oestergaard ST, Poulsen NS, Vissing J. Disease progression and outcome measures in spinobulbar muscular atrophy. Ann. Neurol. 2018;84(5):754&#x2013;765. doi: 10.1002/ana.25345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25345</ArticleId><ArticleId IdType="pubmed">30255951</ArticleId></ArticleIdList></Reference><Reference><Citation>Klickovic U, Zampedri L, Sinclair CDJ, Wastling SJ, Trimmel K, Howard RS, Malaspina A, Sharma N, Sidle K, Emira A, Shah S, Yousry TA, Hanna MG, Greensmith L, Morrow JM, Thornton JS, Fratta P. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity. Neurology. 2019;93(9):e895&#x2013;e907. doi: 10.1212/WNL.0000000000008009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008009</ArticleId><ArticleId IdType="pmc">PMC6745729</ArticleId><ArticleId IdType="pubmed">31391248</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennuto M, Greensmith L, Pradat PF, Sorar&#xf9; G. 210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27&#x2013;29 March, 2015, Naarden, The Netherlands. Neuromusc. Disord. 2015;25(10):802&#x2013;812. doi: 10.1016/j.nmd.2015.06.462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.06.462</ArticleId><ArticleId IdType="pubmed">26206601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatini D, Raggi F, Ruggero S, Seguso M, Mandrioli J, Cagnin A, Briani C, Toffanin E, Gizzi M, Fortuna A, Bello L, Pegoraro E, Musso G, Sorar&#xf9; G. Evaluation of peripherin in biofluids of patients with motor neuron diseases. Ann. Clin. Transl. Neurol. 2021;8(8):1750&#x2013;1754. doi: 10.1002/acn3.51419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51419</ArticleId><ArticleId IdType="pmc">PMC8351396</ArticleId><ArticleId IdType="pubmed">34264016</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP, Kalantar-Zadeh K. Serum creatinine as a marker of muscle mass in chronic kidney disease: Results of a cross-sectional study and review of literature. J. Cachexia Sarcopenia Muscle. 2013;4(1):19&#x2013;29. doi: 10.1007/s13539-012-0079-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13539-012-0079-1</ArticleId><ArticleId IdType="pmc">PMC3581614</ArticleId><ArticleId IdType="pubmed">22777757</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessman SP, Geiger PJ. Transport of energy in muscle: The phosphorylcreatine shuttle. Science. 1981;211(4481):448&#x2013;452. doi: 10.1126/science.6450446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6450446</ArticleId><ArticleId IdType="pubmed">6450446</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, Heilberg IP. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin. J. Am. Soc. Nephrol. 2008;3(2):348&#x2013;354. doi: 10.2215/CJN.02870707.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02870707</ArticleId><ArticleId IdType="pmc">PMC2390952</ArticleId><ArticleId IdType="pubmed">18235143</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutte JE, Longhurst JC, Gaffney FA, Bastian BC, Blomqvist CG. Total plasma creatinine: An accurate measure of total striated muscle mass. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1981;51(3):762&#x2013;766. doi: 10.1152/jappl.1981.51.3.762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1981.51.3.762</ArticleId><ArticleId IdType="pubmed">7327978</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves CRR, Zhang R, Johnstone AJ, Garner R, Nwe PH, Siranosian JJ, Swoboda KJ. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology. 2020;94(9):e921&#x2013;e931. doi: 10.1212/WNL.0000000000008762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008762</ArticleId><ArticleId IdType="pmc">PMC7238944</ArticleId><ArticleId IdType="pubmed">31882526</ArticleId></ArticleIdList></Reference><Reference><Citation>Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, Mendell JR. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 2009;40(3):438&#x2013;442. doi: 10.1002/mus.21420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21420</ArticleId><ArticleId IdType="pmc">PMC2740988</ArticleId><ArticleId IdType="pubmed">19623638</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 2018;89(2):156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdom CJ, Janse van Mantgem MR, van Eijk RPA, Howe SL, van den Berg LH, McCombe PA, Henderson RD, Ngo ST, Steyn FJ. Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2021;28(11):3615&#x2013;3625. doi: 10.1111/ene.15003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15003</ArticleId><ArticleId IdType="pubmed">34216521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, Hirakawa A, Watanabe H, Yamamoto M, Fischbeck KH, Sobue G. A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study. Neuromusc. Disord. 2015;25(7):554&#x2013;562. doi: 10.1016/j.nmd.2015.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.03.008</ArticleId><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, DaRe E, Martinelli I, Bello L, Bertolin C, Pareyson D, Mariotti C, Pegoraro E, Sorar&#xf9; G. Validation of the Italian version of the SBMA functional rating scale as outcome measure. Neurol. Sci. 2016;37(11):1815&#x2013;1821. doi: 10.1007/s10072-016-2666-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-016-2666-y</ArticleId><ArticleId IdType="pubmed">27444956</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris-Love MO, Fernandez-Rhodes L, Joe G, Shrader JA, Kokkinis A, La Pean KA, Auh S, Chen C, Li L, Levy E, Davenport TE, Di Prospero NA, Fischbeck KH. Assessing function and endurance in adults with spinal and bulbar muscular atrophy: Validity of the adult myopathy assessment tool. Rehabil. Res. Pract. 2014;2014:873872. doi: 10.1155/2014/873872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/873872</ArticleId><ArticleId IdType="pmc">PMC4026974</ArticleId><ArticleId IdType="pubmed">24876969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Banno H, Suzuki K, Suga N, Mano T, Atsuta N, Oe H, Watanabe H, Tanaka F, Sobue G. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain. 2012;135(Pt 9):2838&#x2013;2848. doi: 10.1093/brain/aws170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws170</ArticleId><ArticleId IdType="pubmed">22773541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Querin G, Ziff OJ, Zampedri L, Martinelli I, Heller C, Foiani M, Bertolin C, Lu CH, Malik B, Allen K, Rinaldi C, Zetterberg H, Heslegrave A, Greensmith L, Hanna M, Soraru G, Malaspina A, Fratta P. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology. 2019;92(11):e1205&#x2013;e1211. doi: 10.1212/WNL.0000000000007097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007097</ArticleId><ArticleId IdType="pmc">PMC6511101</ArticleId><ArticleId IdType="pubmed">30787165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, Hirakawa A, Suzuki K, Atsuta N, Tsuboi T, Hattori M, Hori A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology. 2018;90(17):e1501&#x2013;e1509. doi: 10.1212/WNL.0000000000005360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005360</ArticleId><ArticleId IdType="pubmed">29572281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000;80(3):1107&#x2013;1213. doi: 10.1152/physrev.2000.80.3.1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2000.80.3.1107</ArticleId><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan R, Ho CS, Chu LM, Donnan S. Relation between plasma creatinine and body size. Clin Chem. 1986;32(2):371&#x2013;373. doi: 10.1093/clinchem/32.2.371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/32.2.371</ArticleId><ArticleId IdType="pubmed">3943202</ArticleId></ArticleIdList></Reference><Reference><Citation>Thongprayoon C, Cheungpasitporn W, Kashani K. Serum creatinine level, a surrogate of muscle mass, predicts mortality in critically ill patients. J. Thorac. Dis. 2016;8(5):E305&#x2013;E311. doi: 10.21037/jtd.2016.03.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2016.03.62</ArticleId><ArticleId IdType="pmc">PMC4842835</ArticleId><ArticleId IdType="pubmed">27162688</ArticleId></ArticleIdList></Reference><Reference><Citation>Banfi G, Del Fabbro M, Lippi G. Serum creatinine concentration and creatinine-based estimation of glomerular filtration rate in athletes. Sports Med. 2009;39(4):331&#x2013;337. doi: 10.2165/00007256-200939040-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00007256-200939040-00005</ArticleId><ArticleId IdType="pubmed">19317520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, Hirakawa A, Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann. Clin. Transl. Neurol. 2016;3(7):537&#x2013;546. doi: 10.1002/acn3.324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.324</ArticleId><ArticleId IdType="pmc">PMC4931718</ArticleId><ArticleId IdType="pubmed">27386502</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, D'Ascenzo C, Peterle E, Ermani M, Bello L, Melacini P, Morandi L, Mazzini L, Silani V, Raimondi M, Mandrioli J, Romito S, Angelini C, Pegoraro E, Sorar&#xf9; G. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology. 2013;80(23):2095&#x2013;2098. doi: 10.1212/WNL.0b013e318295d766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318295d766</ArticleId><ArticleId IdType="pubmed">23645595</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, Tanaka F, Tamakoshi A, Sobue G. Natural history of spinal and bulbar muscular atrophy (SBMA): A study of 223 Japanese patients. Brain. 2006;129(Pt 6):1446&#x2013;1455. doi: 10.1093/brain/awl096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl096</ArticleId><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosini A, Calabrese D, Avato FM, Catania F, Cavaletti G, Pera MC, Toscano A, Vita G, Monaco L, Pareyson D. The Italian neuromuscular registry: A coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet. J. Rare Dis. 2018;13(1):176. doi: 10.1186/s13023-018-0918-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-018-0918-z</ArticleId><ArticleId IdType="pmc">PMC6172847</ArticleId><ArticleId IdType="pubmed">30286784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>